Ozempic Maker Says AI Is Finally Reliable Enough to Produce Sensitive Documents

Multinational companies in regulated industries like pharmaceuticals and insurance have been somewhat reluctant to adopt generative artificial intelligence to handle legally sensitive documents due to the risk of AI-generated mistakes.

That seems to be changing. Take Novo Nordisk, the Danish drugmaker behind Ozempic. The company for years has tested chatbots such as OpenAI’s ChatGPT and models such as Meta Platforms’ Llama to help write documents it files to regulators when submitting a drug for approval, but the technology has been prone to errors, said Louise Lind Skov, who leads the company’s tech strategy. Sometimes it could take employees more time to correct the AI errors than if they’d done everything by hand in the first place, she said.